{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T14:15:00Z","timestamp":1773065700306,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.bbrc.2018.09.106","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T00:20:47Z","timestamp":1538612447000},"page":"733-739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["A combination of irinotecan\/cisplatinum and irinotecan\/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model"],"prefix":"10.1016","volume":"505","author":[{"given":"Tasuku","family":"Kiyuna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Tome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Oshiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masuyo","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiko","family":"Sugisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Razmjooei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sintawat","family":"Wangsiricharoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartosz","family":"Chmielowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara A.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah M.","family":"Dry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun S.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sant","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuminori","family":"Kanaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fritz C.","family":"Eilber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shree Ram","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2018.09.106_bib1","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1245\/s10434-015-5063-5","article-title":"Optimal percent myxoid component to predict outcome in high-grade myxofibrosarcoma and undifferentiated pleomorphic sarcoma","volume":"23","author":"Lee","year":"2016","journal-title":"Ann. Surg Oncol."},{"issue":"3","key":"10.1016\/j.bbrc.2018.09.106_bib2","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1245\/s10434-010-1341-4","article-title":"Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution","volume":"18","author":"Sanfilippo","year":"2011","journal-title":"Ann. Surg Oncol."},{"issue":"2","key":"10.1016\/j.bbrc.2018.09.106_bib3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4081\/rt.2013.e15","article-title":"Myxofibrosarcoma: a diagnostic pitfall","volume":"5","author":"Castronovo","year":"2013","journal-title":"Rare Tumors"},{"issue":"2","key":"10.1016\/j.bbrc.2018.09.106_bib4","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/cncr.26296","article-title":"The enigma of myxofibrosarcoma of the extremity","volume":"118","author":"Mutter","year":"2012","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.bbrc.2018.09.106_bib5","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.bbapap.2017.06.023","article-title":"Discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2) is a novel biomarker of myxofibrosarcoma invasion identified by global protein expression profiling","volume":"1865","author":"Kikuta","year":"2017","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.bbrc.2018.09.106_bib6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijrobp.2010.08.042","article-title":"Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma","volume":"82","author":"Haglund","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bbrc.2018.09.106_bib7","series-title":"WHO classification of Tumours of Soft Tissue and Bone","author":"Fletcher","year":"2013"},{"issue":"11","key":"10.1016\/j.bbrc.2018.09.106_bib8","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/jjco\/hyt119","article-title":"An analysis of factors related to recurrence of myxofibrosarcoma","volume":"43","author":"Kikuta","year":"2013","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbrc.2018.09.106_bib9","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1038\/s41467-018-03891-9","article-title":"Integrated genetic and epigenetic analysis of myxofibrosarcoma","volume":"9","author":"Ogura","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2018.09.106_bib10","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.soc.2016.05.008","article-title":"myxofibrosarcoma","volume":"25","author":"Roland","year":"2016","journal-title":"Surg. Oncol. Clin."},{"key":"10.1016\/j.bbrc.2018.09.106_bib11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00000658-197511000-00011","article-title":"Surgical treatment of 297 soft tissue sarcomas of the lower extremity","volume":"182","author":"Shiu","year":"1975","journal-title":"Ann. Surg."},{"key":"10.1016\/j.bbrc.2018.09.106_bib12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.anorl.2013.09.004","article-title":"Myxofibrosarcoma of the thyroid gland","volume":"131","author":"Darouassi","year":"2014","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"10.1016\/j.bbrc.2018.09.106_bib13","first-page":"711","article-title":"A\u00a0case of retroperitoneal myxofibrosarcoma","volume":"55","author":"Takeda","year":"2009","journal-title":"Hinyokika Kiyo"},{"key":"10.1016\/j.bbrc.2018.09.106_bib14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2010.02.012","article-title":"Clinical development of a potent anti-angiogenic drug","volume":"77","author":"Schutz","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"23","key":"10.1016\/j.bbrc.2018.09.106_bib15","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1002\/cncr.30926","article-title":"Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma","volume":"123","author":"Samuels","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.bbrc.2018.09.106_bib16","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbrc.2018.09.106_bib17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11060-015-2028-2","article-title":"The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide","volume":"127","author":"Strowd","year":"2016","journal-title":"J.\u00a0Neuro Oncol."},{"issue":"9","key":"10.1016\/j.bbrc.2018.09.106_bib18","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/cncr.11730","article-title":"A\u00a0phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma","volume":"98","author":"Talbot","year":"2003","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.bbrc.2018.09.106_bib19","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1002\/cncr.26098","article-title":"Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor","volume":"117","author":"Park","year":"2011","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.bbrc.2018.09.106_bib20","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1158\/1078-0432.CCR-13-0776","article-title":"Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics","volume":"19","author":"Stacchiotti","year":"2013","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.bbrc.2018.09.106_bib21","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/cncr.21384","article-title":"Spanish Group for Research on Sarcomas. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas","volume":"104","author":"Garcia del Muro","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bbrc.2018.09.106_bib22","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0959-8049(98)00403-1","article-title":"Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group","volume":"35","author":"Woll","year":"1999","journal-title":"Eur. J. Canc."},{"issue":"3","key":"10.1016\/j.bbrc.2018.09.106_bib23","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ijrobp.2008.11.032","article-title":"Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma","volume":"75","author":"Jakob","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"7","key":"10.1016\/j.bbrc.2018.09.106_bib24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ctrv.2006.07.001","article-title":"Irinotecan in the treatment of colorectal cancer","volume":"32","author":"Fuchs","year":"2006","journal-title":"Canc. Treat Rev."},{"issue":"4","key":"10.1016\/j.bbrc.2018.09.106_bib25","first-page":"1055","article-title":"Irinotecan as a second-line monotherapy for small cell lung cancer","volume":"12","author":"Sevinc","year":"2011","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"issue":"1","key":"10.1016\/j.bbrc.2018.09.106_bib26","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1186\/s12885-018-4715-9","article-title":"Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis","volume":"18","author":"Xu","year":"2018","journal-title":"BMC Canc."},{"issue":"4","key":"10.1016\/j.bbrc.2018.09.106_bib27","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/COC.0000000000000068","article-title":"Randomized phase II trial of irinotecan\/docetaxel or irinotecan\/docetaxel plus cetuximab for metastatic pancreatic cancer: an eastern cooperative oncology group study","volume":"39","author":"Burtness","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2018.09.106_bib28","doi-asserted-by":"crossref","first-page":"e644","DOI":"10.14694\/EdBook_AM.2015.35.e644","article-title":"Systemic therapy for osteosarcoma and Ewing sarcoma","author":"Meyers","year":"2015","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.bbrc.2018.09.106_bib29","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/pbc.22206","article-title":"Irinotecan and temozolomide for ewing sarcoma: the memorial sloan-kettering experience","volume":"53","author":"Casey","year":"2009","journal-title":"Pediatr. Blood Canc."},{"key":"10.1016\/j.bbrc.2018.09.106_bib30","doi-asserted-by":"crossref","first-page":"11119","DOI":"10.18632\/oncotarget.24264","article-title":"Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models","volume":"9","author":"Kawaguchi","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2018.09.106_bib31","first-page":"901","article-title":"A\u00a0metastatic-orthotopic transplant nude-mouse model of human patient breast cancer","volume":"13","author":"Fu","year":"1993","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2018.09.106_bib32","first-page":"283","article-title":"Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens","volume":"13","author":"Fu","year":"1993","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2018.09.106_bib33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jso.23816","article-title":"Selective efficacy of zoledronic acid on metastasis in a patient-derived orthotopic xenograph (PDOX) nude-mouse model of human pancreatic cancer","volume":"111","author":"Hiroshima","year":"2015","journal-title":"J.\u00a0Surg. Oncol."},{"key":"10.1016\/j.bbrc.2018.09.106_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117417","article-title":"Establishment of a patient-derived orthotopic xenograph (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern","volume":"10","author":"Hiroshima","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2018.09.106_bib35","doi-asserted-by":"crossref","first-page":"9345","DOI":"10.1073\/pnas.88.20.9345","article-title":"Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens","volume":"88","author":"Fu","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbrc.2018.09.106_bib36","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/ijc.2910510626","article-title":"A\u00a0new patient-like metastatic model of human lung cancer constructed orthotopically with intact tissue via thoracotomy in immunodeficient mice","volume":"51","author":"Wang","year":"1992","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.bbrc.2018.09.106_bib37","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/ijc.2910530414","article-title":"Orthotopic transplantation of histologically intact clinical specimens of stomach cancer to nude mice: correlation of metastatic sites in mouse and individual patient donors","volume":"53","author":"Furukawa","year":"1993","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.bbrc.2018.09.106_bib38","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2017.12.028","article-title":"Recombinant methioninase in combination with DOX overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma","volume":"417","author":"Igarashi","year":"2018","journal-title":"Canc. Lett."},{"issue":"432","key":"10.1016\/j.bbrc.2018.09.106_bib39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.canlet.2018.06.016","article-title":"Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer","volume":"28","author":"Kawaguchi","year":"2018","journal-title":"Canc. Lett."},{"key":"10.1016\/j.bbrc.2018.09.106_bib40","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrc3972","article-title":"Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts","volume":"15","author":"Hoffman","year":"2015","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.bbrc.2018.09.106_bib41","doi-asserted-by":"crossref","first-page":"75874","DOI":"10.18632\/oncotarget.16548","article-title":"Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model","volume":"8","author":"Igarashi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2018.09.106_bib42","doi-asserted-by":"crossref","first-page":"103129","DOI":"10.18632\/oncotarget.20789","article-title":"The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and CDKN2A deletion: direction for third-line patient therapy","volume":"8","author":"Miyake","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2018.09.106_bib43","doi-asserted-by":"crossref","first-page":"7774","DOI":"10.18632\/oncotarget.22892","article-title":"Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model","volume":"9","author":"Igarashi","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2018.09.106_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120358","article-title":"Tumor-targeting Salmonella typhimurium A1-R in combination with Trastuzumab eradicates HER-2-positive cervical cancer cells in patient-derived mouse models","volume":"10","author":"Hiroshima","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2018.09.106_bib45","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/jcb.24769","article-title":"Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX)","volume":"115","author":"Hiroshima","year":"2014","journal-title":"J.\u00a0Cell. Biochem."},{"key":"10.1016\/j.bbrc.2018.09.106_bib46","doi-asserted-by":"crossref","first-page":"12783","DOI":"10.18632\/oncotarget.7226","article-title":"Tumor-targeting Salmonella typhimurium A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft PDOX model","volume":"7","author":"Murakami","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2018.09.106_bib47","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.bbrc.2018.02.174","article-title":"Tumor-targeting Salmonella typhimurium A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma in patient-derived orthotopic xenograft (PDOX) nude-mouse models","volume":"497","author":"Igarashi","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2018.09.106_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160882","article-title":"Efficacy of tumor-targeting Salmonella typhimurium A1-R on a melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse model","volume":"11","author":"Yamamoto","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bbrc.2018.09.106_bib49","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1016\/j.bbrc.2018.08.097","article-title":"Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma","volume":"503","author":"Kawaguchi","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.bbrc.2018.09.106_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2018.e00643","article-title":"Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations","volume":"4","author":"Miyake","year":"2018","journal-title":"Heliyon"},{"key":"10.1016\/j.bbrc.2018.09.106_bib51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41392-018-0016-7","article-title":"Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting S.\u00a0typhimurium A1-R is superior to first-line chemotherapy","volume":"3","author":"Miyake","year":"2018","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bbrc.2018.09.106_bib52","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.4161\/cc.9.22.13744","article-title":"Vessel destruction by tumor-targeting Salmonella typhimurium A1-R is enhanced by high tumor vascularity","volume":"9","author":"Liu","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbrc.2018.09.106_bib53","first-page":"159","article-title":"Tumor-targeting Salmonella typhimurium A1-R inhibits osteosarcoma angiogenesis in the in\u00a0vivo Gelfoam\u00ae assay visualized by color-coded imaging","volume":"38","author":"Kiyuna","year":"2018","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2018.09.106_bib54","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.bbrc.2018.02.174","article-title":"Tumor-targeting Salmonella typhimurium A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma in patient-derived orthotopic xenograft (PDOX) nude-mouse models","volume":"497","author":"Igarashi","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"52","key":"10.1016\/j.bbrc.2018.09.106_bib55","doi-asserted-by":"crossref","first-page":"85929","DOI":"10.18632\/oncotarget.13231","article-title":"Tumor-targeting Salmonella typhimurium A1-R combined with Temozolomide regresses malignant melanoma with a BRAF-V600 mutation in a patient-derived orthotopic xenograft (PDOX) model","volume":"7","author":"Kawaguchi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2018.09.106_bib56","doi-asserted-by":"crossref","DOI":"10.4143\/crt.2017.529","article-title":"Pembrolizumab for refractory metastatic myxofibrosarcoma: a case report","author":"Song","year":"2018","journal-title":"Cancer Res Treat."},{"issue":"7","key":"10.1016\/j.bbrc.2018.09.106_bib57","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13569-017-0082-6","article-title":"Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma","volume":"22","author":"Colia","year":"2017","journal-title":"Clin. Sarcoma Res."},{"issue":"8","key":"10.1016\/j.bbrc.2018.09.106_bib58","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.ejca.2014.01.020","article-title":"Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801\/BIRIP trial)","volume":"50","author":"Higuchi","year":"2014","journal-title":"Eur. J. Canc."},{"issue":"2","key":"10.1016\/j.bbrc.2018.09.106_bib59","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4143\/crt.2016.121","article-title":"Phase II study of irinotecan and cisplatin combination chemotherapy in metastatic, unresectable esophageal cancer","volume":"49","author":"Kim","year":"2017","journal-title":"Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.bbrc.2018.09.106_bib60","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1002\/cncr.26591","article-title":"Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer","volume":"118","author":"Ilson","year":"2012","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.bbrc.2018.09.106_bib61","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1002\/cncr.25349","article-title":"Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer","volume":"116","author":"Knox","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bbrc.2018.09.106_bib62","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.bjc.6690656","article-title":"Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer","volume":"81","author":"Sugiyama","year":"1999","journal-title":"Br. J. Canc."},{"issue":"9","key":"10.1016\/j.bbrc.2018.09.106_bib63","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/cncr.10918","article-title":"Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors","volume":"95","author":"Miki","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2018.09.106_bib64","article-title":"Randomized phase III trial of irinotecan plus cisplatin versus etoposide plus cisplatin in chemotherapy-Na\u00efve Korean patients with extensive-disease small cell lung cancer","author":"Kim","year":"2018","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.bbrc.2018.09.106_bib65","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/pbc.24621","article-title":"Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma","volume":"60","author":"Raciborska","year":"2013","journal-title":"Pediatr. Blood Canc."},{"issue":"7","key":"10.1016\/j.bbrc.2018.09.106_bib66","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1080\/0284186X.2018.1449250","article-title":"Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients","volume":"57","author":"Palmerini","year":"2018","journal-title":"Acta Oncol."},{"issue":"8","key":"10.1016\/j.bbrc.2018.09.106_bib67","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/annonc\/mdy197","article-title":"Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation","volume":"29","author":"Morano","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrc.2018.09.106_bib68","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.4161\/15384101.2014.964115","article-title":"Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy","volume":"13","author":"Yano","year":"2014","journal-title":"Cell Cycle"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X18320333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X18320333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:16:31Z","timestamp":1605140191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X18320333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0006291X18320333"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2018.09.106","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A combination of irinotecan\/cisplatinum and irinotecan\/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2018.09.106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}